MDGL
Madrigal Pharmaceuticals, Inc.
$434.24
-4.21%
2026-10-23
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Key Fundamentals
Forward P/E
53.67
EPS (TTM)
$-14.00
ROE
-53.3%
Revenue Growth (YoY)
71.2%
Profit Margin
-25.3%
Debt/Equity
66.40
Price/Book
22.78
Beta
-0.99
Market Cap
$11.93B
Avg Volume (10D)
237K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$552.08
60D Low
$433.31
Avg Volume
280K
Latest Close
$434.24
Get breakout alerts for MDGL
Sign up for Breakout Scanner to receive daily notifications when MDGL triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Madrigal Pharmaceuticals, Inc. (MDGL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MDGL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MDGL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.